Dengue Fever
99
7
10
69
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Published Results
36 trials with published results (36%)
Research Maturity
69 completed trials (70% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
2.0%
2 terminated out of 99 trials
97.2%
+10.7% vs benchmark
16%
16 trials in Phase 3/4
52%
36 of 69 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 69 completed trials
Clinical Trials (99)
IC14 in Adult Patients With Dengue Fever
Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children
A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)
A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers the Chance of Hospital Stays for Dengue
Xpert® Tropical Fever Test on GeneXpert® Edge X System
Prediction of Infectious Diseases in LMICs Using Electronic Health Record Data
International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR)
A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults
A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan
A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)
Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection
To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated Thrombocytopenia
Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)
Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections
Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia
Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)
A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers
The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever
A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia